GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms

Rizzo, Manfredi, Nikolic, Dragana, Patti, Angelo Maria, Mannina, Carlo, Montalto, Giuseppe, McAdams, Brooke S., Rizvi, Ali A., Cosentino, Francesco·2018·Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
DOI 10.1016/j.bbadis.2018.05.012

Cited by (152)

Items 101–152 of 152

  1. Experimental and Emerging Free Fatty Acid Receptor Agonists for the Treatment of Type 2 Diabetes
    Angelo Maria Patti, Rosaria Vincenza Giglio, Νικόλαος Παπάνας, Dragoş Şerban, Anca Pantea Stoian, Kalliopi Pafili, Khalid Al‐Rasadi, Kanya Rajagopalan, Ali Abbas Rizvi, Marcello Ciaccio et al. · 2022 · Medicina
  2. The weight reduction mediated by anti-obesity medication and the cardiovascular outcome
    Yuchen Guo, Lin Chu, Xiaoling Cai, Han Wu, Jingya Yan, Zonglin Li, Ruoyang Jiao, Shuzhen Bai, Wenjia Yang, Fang Lv et al. · 2024 · iScience
  3. Evaluating the Impact of Novel Incretin Therapies on Cardiovascular Outcomes in Type 2 Diabetes: An Early Systematic Review
    Teodor Salmen, Claudia-Gabriela Potcovaru, Ioana-Cristina Bica, Rosaria Vincenza Giglio, Angelo Maria Patti, Roxana Adriana Stoica, Marcello Ciaccio, Mohamed El‐Tanani, Andrej Janež, Manfredi Rizzo et al. · 2024 · Pharmaceuticals
  4. Tirzepatide, a novel, dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist for the ongoing diabesity epidemic: the dawn of a new era?
    Imran Rashid Rangraze, Dimitrios Patoulias, Paschalis Karakasis, Mohamed El‐Tanani, Manfredi Rizzo · 2024 · Expert Review of Clinical Pharmacology
  5. Effect of Glucagon‐Like Peptide‐1 Receptor Agonists on Cardiometabolic Risk Factors in Type 1 Diabetes Mellitus: A Systematic Review and Meta‐Analysis
    Yizhu Chen, Yu-Fei Tang, Rui Yue, Bo Yang, Ai-Hong Wang, Yang Long, Yong Xu, Chen-Lin Gao · 2025 · Diabetes/Metabolism Research Reviews
  6. Diabetes and COVID-19: What 2 Years of the Pandemic Has Taught Us
    Anca Pantea Stoian, Péter Kempler, Thomas M. Stulnig, Ali Abbas Rizvi, Manfredi Rizzo · 2021 · Metabolic Syndrome and Related Disorders
  7. The impact of DPP-4 inhibitors on cardiovascular disease treatment: a comprehensive review of current therapeutic strategies and future directions
    Toka Elemary, Mina Nicola, Mohamed E. A. Abdelrahim, Dalia K. Zaafar · 2025 · Molecular Biology Reports
  8. Semaglutide in Cardiometabolic Diseases: SELECTing the Target Population
    Francesco Natale, Ettore Luisi, Rosa Franzese, Noemi Mollo, Achille Solimene, Valentina Maria Caso, Andrea Corvino, Paolo Golino, Giovanni Cimmino · 2024 · Journal of Cardiovascular Development and Disease
  9. Biosimilar and generic formulations of novel antidiabetic drugs: the role of liraglutide in clinical pharmacology of type 2 diabetes
    Manfredi Rizzo, Francesco Cosentino, Christos Socrates Mantzoros · 2022 · Expert Review of Clinical Pharmacology
  10. GLP-1 Receptor Agonists and Cardiovascular and Kidney Outcomes by Body Mass Index in Type 2 Diabetes
    Prerana Ramadurgum, Kunal M. Sharma, Alec Pinon, Lakshmi Prasanna Vaishnavi Kattamuri, Monica Botros · 2026 · Current Cardiology Reports
  11. Benefits of Supplementing a GLP-1 Type Medication With Physical Activity
    Elizabeth A. Ablah, Mary T. Imboden, Anna L. Zendell, Michael Hosking, Robert E. Anderson, Kipchoge VanHoose, Neil E. Peterson, Janet R. Wojcik, Nicolaas P. Pronk, Murray Harber et al. · 2025 · American Journal of Health Promotion
  12. Obesity and COVID-19: insights from two pandemics
    Yu. Sh. Khalimov, Павел Владимирович Агафонов, Elena B. Kireeva · 2022 · Journal Infectology
  13. Effects of new hypoglycemic drugs on patients with heart failure: a systematic review and network meta-analysis
    Ruirui Song, Fang Liu, Xiaojing Shi, Songtao Sun, Jun Chen, Hong-mei Gao · 2024 · Postgraduate Medical Journal
  14. Microvascular and macrovascular effects of liraglutide
    Domenico Cianflone, Ali Abbas Rizvi, Manfredi Rizzo · 2019 · International Journal of Cardiology
  15. Glucagon-like peptide-1 receptor agonists in patients with anthracycline related cardiac dysfunction
    Isabel G. Scalia, Ramzi Ibrahim, Mahmoud Hassan Abdelnabi, Hoang Nhat Pham, Juan Farina, Milagros Pereyra, Kwan Seung S Lee, Balaji K. Tamarappoo, Reza Arsanjani, Chadi Ayoub · 2025 · Cardio-Oncology
  16. Traditional and Modern Predictors of Atherosclerotic Cardiovascular Disease in Patients with T2D and MASLD
    Cosmina-Theodora Vulpescu (Diaconu), Marius-Costin Chitu, Teodor Salmen, Anca Pantea Stoian, Cristian Guja · 2026 · Diagnostics
  17. Dyslipidemia in Metabolic Syndrome
    Sue-Anne Ee Shiow Toh, Michelle H. Lee · 2023 · Springer eBooks
  18. Molecular Endocrinology and Metabolism in 2021: What’s New
    Manfredi Rizzo · 2021 · International Journal of Molecular Sciences
  19. Lipid metabolism disorders in metabolic syndrome
    Ekaterina A Polyakova · 2025 · Russian Journal of Cardiology
  20. The Conventional and Alternative Therapeutic Approaches in Arterial Stiffness Management
    Joseph Iharinjaka Randriamboavonjy, Valeria Conti, Ines Mazza, Thierry Ragot, Charles Andrianjara, Herintsoa Rafatro, Angela Tesse · 2026 · Pharmaceutics
  21. Potential Antiarrhythmic Mechanisms of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs)
    Jianhong Li, Kun Fu, Jiaqian Zhao, Ying Zou, Li Li, Qiuyuan Huang, Limei LONG, Xianhong Ou, Ming Lei, Chunxiang Zhang et al. · 2026 · Drug Design Development and Therapy
  22. Lifestyle Medicine as Co-Therapy During Incretin-Based Anti-Obesity Pharmacotherapy: Integrating Physical Activity, Nutrition, and Behavioral Strategies for Long-Term Success
    Marta Mallardo, Antonietta Messina, Vincenzo Monda, Marco La Marra, Antonietta Monda, Salvatore Allocca, Maria Casillo, Girolamo Di Maio, Pasquale Perrone, Aurora Daniele et al. · 2026 · Nutrients
  23. Knockdown of SNW1 ameliorates brain microvascular endothelial cells injury by inhibiting NLRP3 inflammasome activation
    Zhen Tao, Hongwei Guo, Jigang Tang, Ming Cheng · 2021 · Archives of Medical Science
  24. Review of Pharmaceutical and Therapeutic Approaches for Type 2 Diabetes and Related Disorders
    Mohammad Saeedi, Fatemeh Mehranfar, Fateme Ghorbani, Mohammadali Eskandari, Majid Ghorbani, Ali Babaeizad · 2022 · Recent Patents on Biotechnology
  25. Abordaje práctico de la semaglutida en el paciente con diabetes tipo 2
    Carlos Escobar, Almudena Castro, Jorge Francisco Gómez Cerezo, José Luis Górriz, Juan Carlos Obaya, Rocío Villar‐Taibo · 2022 · Revista Española de Cardiología Suplementos
  26. Pediatric Metabolic and Bariatric Surgery and Antiobesity Medications: Weighing Efficacy, Risks, and Future Directions
    Justine O. Chinn, Jennifer Woo Baidal, Janey S.A. Pratt, W. Elizabeth Shepard, Gillian L. Fell · 2025 · The Journal of Pediatrics
  27. Reprint of: Blood Sugar Regulation for Cardiovascular Health Promotion and Disease Prevention
    Peter E. H. Schwarz, Patrick Timpel, Lorenz Harst, Colin James Greaves, Mohammed Kumail Ali, Jeffrey D. Lambert, Mary Beth Weber, Mohamad Musbah Almedawar, Henning Morawietz · 2018 · Journal of the American College of Cardiology
  28. Цукровий діабет і COVID-19: сучасні погляди на патогенетичні питання клініки та терапії
    Vitaliy Tsymbalyuk, Mykola D. Tronko, Yu.G. Antypkin, В.В. Попова · 2021 · Endokrynologia
  29. Update on the Management of Diabetic Dyslipidaemia
    Iciar Martin Timon, Cristina Sevillano-Collantes, María García-Domínguez, Juan José Marín-Peñalver, Beatriz Ugalde-Abiega, Francisco Javier del Cañizo-Gómez · 2018 · EMJ Diabetes
  30. Dyslipidemia in Metabolic Syndrome
    Sue-Anne Ee Shiow Toh, Michelle H. Lee · 2023 · Springer eBooks
  31. Metabolic Syndrome and Kidney Diseases
    Vincent Boima, Alexander B. Agyekum, Augustus K. Eduafo · 2023 · Springer eBooks
  32. GLP-1: soltanto la glicemia?
    Giuseppina Tiziana Russo, Annalisa Giandalia, Domenico Cucinotta · 2019 · L Endocrinologo
  33. Kardiovaskuläre Effekte von GLP-1-Rezeptoragonisten
    Florian Kahles, Michael Lehrke · 2020 · Diabetes aktuell
  34. Assessing the Continuation of Glucagon-Like Peptide-1 Receptor Agonists When Weight and HBA1C Are Not Reduced
    Rona Zhou, Karsten Duncan, Julio Lopez, Kjersti Rich, Arthur Swislocki · 2020 · Metabolic Syndrome and Related Disorders
  35. Diabetes mellitus in combination with COVID-19: modern views on therapy
    Vitaliy I. Tsymbaliuk, Mykola D. Tronko, Y.G. Antypkin, S.V. Kushnirenko, В.В. Попова · 2021 · Reproductive Endocrinology
  36. Liraglutide may affect visceral fat accumulation in diabetic rats via changes in FTO, AMPK, and AKT expression
    Shan Xiao, Ye Yang, Yuetong Liu, Jun Zhu · 2021 · International Journal of Diabetes in Developing Countries
  37. Agonisti del recettore del GLP1 e infiammazione: non solo compenso glicemico
    Gabriele Costanzo, Francesco Frasca · 2022 · L Endocrinologo
  38. Research Progress of Dipeptidyl Eptidase 4 Inhibitors in Elderly Patients with Type 2 Diabetes Mellitus Complicated with Atherosclerosis
    泽洋 赵 · 2023 · Advances in Clinical Medicine
  39. Metabolic Syndrome and Kidney Diseases
    Vincent Boima, Alexander B. Agyekum, Augustus K. Eduafo · 2023 · Springer eBooks
  40. La medicina cardiometabolica nell’obesità
    2024 · il Diabete
  41. Pre/Clinical Studies and Mechanisms of Action of Different Approaches Particularly Using Medicinal Plant-Derived Compounds to Reduce Both High Blood Glucose and Pressure Avoiding Tendency to Arterial Stiffness
    Joseph Iharinjaka Randriamboavonjy, Herintsoa Rafatro, Charles Andrianjara · 2024 · SSRN Electronic Journal
  42. IMPACT OF CELEBRITY STATEMENTS ON INTERNET SEARCHES ON THE USE OF SEMAGLUTIDE FOR WEIGHT LOSS
    Local Health Unit of Trapani, ASP Trapani, Trapani, Italy, Sandro Provenzano, Omar Enzo Santangelo, Regional Health Care and Social Agency of Lodi, ASST Lodi, Lodi, Italy · 2025 · Avicenna Bulletin
  43. Effetti a lungo termine della liraglutide sui parametri glico-metabolici, sulle lipoproteine a bassa densità piccole e dense e sullo spessore medio intimale carotideo nei pazienti con diabete mellito di tipo 2: studio prospettico di 5 anni
    Rosaria Vincenza Giglio, Caterina Maria Gambino, Angelo Maria Patti, Concetta Scazzone, Viviana Maggio, Elena MURATORE, Luisa Agnello, Manfredi RIZZO, Marcello Ciaccio · 2025 · Biochimica Clinica
  44. Clinical outcomes and 30-day readmission following heart failure hospitalization in patients previously treated for obesity with GLP-1 agonist versus bariatric surgery
    Nameer E. Ascandar, Bobby Malik, Waqas Qureshi, Aysu Erdemir, Eduardo J. Lazaro, Olugbenga Oyesanmi, Sabry A. Omar, Robert J. Subbiondo, Michael Schandorf-Lartey · 2025 · Next research.
  45. The impact of preoperative antiobesity medications on weight loss in adolescents undergoing metabolic and bariatric surgery – a COSMIC study
    Justine O. Chinn, Mark Shacker, Kelly Brennan, Michael A. Kochis, Alyssa E. Stetson, Christa Bizimana, Josélio Rodrigues de Oliveira Filho, Matthew A. Hornick, Janey S.A. Pratt, Marwa Abu El Haija et al. · 2025 · Surgery for Obesity and Related Diseases
  46. Additional file 1 of The differences of serum lipid profiles between primary aldosteronism and essential hypertension: a meta-analysis and systematic review
    Worapaka Manosroi, Pitchaporn Phudphong, Pichitchai Atthakomol, Mattabhorn Phimphilai · 2022 · Figshare
  47. Prevention and Treatment Strategies in Cardiovascular–Renal–Metabolic Syndrome
    Daniela Maria Tănase, Ioana Bianca Anton, Evelina Maria Gosav · 2025 · Springer eBooks
  48. Managing patients with cardiovascular-kidney-metabolic syndrome: a guideline-driven practical guide for primary care physicians
    Steve Fordan, Imran Afridi, Andrew Garza, Roberto L. Collazo-Maldonado · 2026 · Postgraduate Medicine
  49. Dose‐dependent effects of oral semaglutide on arterial stiffness and the additive role of SGLT‐2 inhibitors in type 2 diabetes
    Takao Sato, Toshihiro Miyamoto, Ryoma Fukuoka, Kazumasa Sugimoto, Yoko Tanimoto, Takashi Nakayama, Kojiro Tanimoto, Koichiro Sugimura, Yoshihide Fujimoto, Akio Kawamura · 2026 · British Journal of Clinical Pharmacology
  50. Liraglutide reprograms vascular smooth muscle cell metabolism to suppress extracellular matrix remodeling in diabetic atherosclerosis
    Kun Zhu, Hanxiu Liu, Ni He, Haoyang Wang, Jing Liu, Qinhu Zhang, Zhongwei Liu · 2026 · Journal of Diabetes Investigation
  51. Endothelial Dysfunction and Obesity: New Diagnostic and Therapeutic Strategies
    Rosaria Vincenza Giglio, Sanja Dj Stankovic, Angelo Maria Patti, Manfredi Rizzo, Marcello Ciaccio · 2026 · International Journal of Molecular Sciences
  52. Letter to the Editor on “Preoperative GLP-1 Receptor Agonists and Thromboinflammatory Markers in Patients Undergoing Abdominoplasty: A Prospective Monocentric Study”
    Mahin Nosratzehi, Shahin Nosratzehi, Mehdi Rostami · 2026 · Aesthetic Plastic Surgery